Predicting the Risk of in-Hospital Mortality in Patients with HIV-Associated Talaromyces Marneffei Infection

Download Article

DOI: 10.21522/TIJAR.2014.09.03.Art003

Authors : Thanh Nguyen Tat, Dat Nguyen Tat

Abstract:

Disseminated Talaromyces marneffei infection (formerly termed penicilliosis) is the third most common microbiologically confirmed opportunistic infection in Southeast Asia, with mortality of up to 30% despite antifungal therapy. There are restrictive clinical algorithms to predict treatment outcomes. A total of 513 patients with microbiology-confirmed HIV-associated talaromycosis were included in the analysis. Poor outcome was observed in 143/513 patients (27.9%). In the univariate logistic regression analysis, hepatomegaly and splenomegaly were protective factors. Shorter duration of illness, higher respiratory rates, dyspnea, AIDS-associated central nervous system syndromes, platelet counts <50,000 cells/mL, aspartate transaminase (AST) >300 U/L, alanine transaminase (ALT) >150 U/L, serum creatinine >110 µmol/L were predictors of poor outcome. In the multivariate logistic regression analysis, shorter days of illness, higher respiratory rates, platelet counts <50,000 cells/mL, AST >300 U/L and serum creatinine >110 µmol/L, active tuberculosis (TB) and/or ongoing TB induction treatment and AIDS-associated central nervous system syndromes were independent predictors of poor outcome. The prognostic scores ranged from 0 to 19, corresponding to a mortality risk of 0% to 100%. The internal validation showed acceptable discrimination (AUC=0.68) and calibration slope (0.93). The Brier score for model performance was 0.14. We developed a simple scoring system that can predict the risk of death in patients with HIV-associated talaromycosis based on routinely measured characteristics on admission. The scoring system will be further externally validated using other cohorts in the region.
Keywords: Talaromyces marneffei, Invasive fungal infections, Mortality, Prognostic model, Vietnam.

References:

[1] Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110-3.

[2] Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbio Rev. 2006; 19:95-110.

[3] Nga TV, Parry CM, Le T, Lan NPH, Diep TS, Campbell J.I. The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: bloodstream infection trends over 15 years in southern Vietnam. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2012; 106:26-34.

[4] Qi T, Zhang R, Shen Y. Etiology, and clinical features of 229 cases of bloodstream infection among Chinese HIV/AIDS patients: a retrospective cross-sectional study. Eur J Clin Microbol Infect Dis. 2016; 35:1767-70.

[5] Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, et al. Epidemiology, Seasonality, and Predictors of Outcome of AIDS-Associated Penicillium marneffei Infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011; 52:945–952.

[6] Larsson M, Nguyen LH, Wertheim HF, Dao TT, Taylor W, Horby P, et al. Clinical characteristics, and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam. AIDS Res Ther. 2012; 9:24.

[7] Son VT, Khue PM, Strobel M. Penicilliosis and AIDS in Hai Phong, Vietnam: Evolution and predictive factors of death. Med Mal Infect. 2014; 44:495-501.

[8] Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013; 13:464.

[9] Hu Y, Zhang J, Li X, Yang Y, Zhang Y, Ma J, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013; 175:57-67.

[10] Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, et al. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. N Engl J Med. 2017; 376:2329-2340.

[11] Narayanasamy S, Dat VQ, Thanh NT, Ly VT, Chan JFW, Yuen KY et al. A global call for talaromycosis to be recognised as a neglected tropical disease. The Lancet Global Health. 2021; 9: e1618-e1622.

[12] Viviani MA, Tortorano AM. P marneffei. In: Ajello L, Hay RJ, editors. Medical mycology Topley and Wilson’s microbiology and microbial infections. 9th ed. Vol 4. London: Edward Arnold; 1998. pp. 409–19.

[13] Steyerberg EW. Clinical Prediction Models: a practical approach to development, validation, and updating. New York: Springer; 2010.

[14] The R Project for Statistical Computing, version 4.1.1, 2021. Available at https://www.r-project.org/. Accessed and cited on 15 April 2022.

[15] Van Buuren S, Groothuis-Oudshoorn K. MICE: Mulrivariate Imputation by Chained Equations in R. Journal of Statistical Software, 2011, Vol 45, issue 3. Available at: https://www.jstatsoft.org/article/view/v045i03. Accessed and cited on 15 April 2022.

[16] Harrell FE. Regression Modeling Strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer-Verlag; 2001.

[17] Qin Y, Zhou Y, Lu Y, Chen H, Jiang Z, He K, et al. Multicentre derivation, and validation of a prognostic scoring system for mortality assessment in HIV-infected patients with talaromycosis. Mycoses. 2021;64(2):203-211.

[18] Klus J, Ly VT, Chan C, Le T. Prognosis, and treatment effects of HIV-associated talaromycosis in a real-world patient cohort. Med Mycol. 2021; 59(4):392-399.

[19] Qin Y, Zhou Y, Lu Y, Chen H, Jiang Z, He K, et al. Multicentre derivation, and validation of a prognostic scoring system for mortality assessment in HIV-infected patients with talaromycosis. Mycoses. 2021; 64:203-211.

[20] Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010; 21:128-38.